References

  1. Gerich JE. Is insulin resistance the principal cause of type 2 diabetes?. Diabetes Obesity and Metabolism 1999; 1: 257-263.
  2. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependant diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. NEJM 1996; 334 (12): 777-783.
  3. Mitrakou A, Kelly D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390.
  4. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the 'natural history' of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Research and Clinical Practice 1994; 26: 177-187.
  5. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabetic Medicine 1996; 13: S19-S24.
  6. Home PD. Rapid-acting insulin secretagogues: A clinical need?. Experimental and Clinical Endocrinology and Diabetes 1999; 107: S115-S119.
  7. Crepaldi G, Del Prato S. What therapy do our NIDDM patients need? Insulin releasers. Diabetes Research and Clinical Practice 1995; 28: S159-S165.
  8. Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism: Clinical and Experimental 1997; 46: 40-43.
  9. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
  10. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetic Medicine 1998; 15: 188-193.
  11. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabetic Medicine 1997; 14: S6-S11.
  12. Tuomilehto J, Qiao Q, Borch-Johnsen K, Balkau B, DECODE study group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
  13. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
  14. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000; 23: 518-523.
  15. Van Gaal L, Van Acker KL, De Leeuw IO. Repaglinide improves blood glucose control in sulphonylurea-naïve tupe 2 diabetes. Diabetes Res Clin Pract 2001; 53: 141-148.
  16. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21: 1897-1903.
  17. Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. International Journal of Obesity 2000; 24: S38-S44.
  18. Schwartz SL, Goldberg RB, Strange P. Repaglinide in type 2 diabetes: A randomized, double-blind, placebo-controlled, dose-response study. Diabetes 1998; 47: A98-A98.
  19. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. Journal of Clinical Pharmacology 2000; 40: 49-57.
  20. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care 2001; 24: 11-15.
  21. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
  22. Rasking P, McGill J, Halle P, Khutoryansky N, Santiago O, Repaglinide/Rosiglitazone Combination Therapy of ype 2 diabetes. Diabetes 2001; 50 (suppl. 2): A128.
  23. Jovanovic L, Jain R, Greco S, Hale P, Khutoryansky N, Santiago O. Diabetes 2001; 50 (Suppl. 2): A439
  24. Landin-Olsson M, Brogard JMM, Eriksson J, Rasmussen M, Clauson P. The efficacy of repaglinide administered in combination with bedtime NPH-insulin in patients with type 2 diabetes: A randomized semi-blinded, parallel-group, multi-centre trial. Diabetes 1999; 48: A117-A117.
  25. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety 1994; 11: 223-241.
  26. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Research and Clinical Practice 1999; 43: 155-166.
  27. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas?. Clinical Pharmacokinetics 1998; 34: 181-188.
  28. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes?. International Journal of Obesity 2000; 24: S21-S31.
  29. Gill GV, Huddle KR. Hypoglycemic admissions among diabetic patients in Soweto, South Africa. Diabetic Medicine 1993; 10: 181-183.
  30. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabetic Medicine 1999; 16: 586-590.
  31. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22: 789-794.
 
Copyright © 2012 European Prescriber Guide
Printed on 28/05/2012 5:24 PM